List of Excipients in Branded Drug PRED MILD

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	PRED MILD	prednisolone acetate	11980-174	BENZALKONIUM CHLORIDE
Allergan Inc	PRED MILD	prednisolone acetate	11980-174	BORIC ACID
Allergan Inc	PRED MILD	prednisolone acetate	11980-174	EDETATE DISODIUM

PRED MILD Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 13, 2026

PRED MILD is prednisolone acetate ophthalmic suspension, 0.12%, a topical corticosteroid for ocular inflammation. Its commercial value is driven less by active-ingredient exclusivity than by formulation execution: particle suspension, redispersibility, preservative tolerability, sterility, container-closure performance, and reliable ophthalmic delivery. The product presents a low-barrier generic opportunity for manufacturers with ophthalmic suspension capabilities, while differentiated opportunities center on preservative-free delivery, improved comfort, unit-dose packaging, and formulation extensions.

What is PRED MILD and how is it formulated?

PRED MILD contains prednisolone acetate at 0.12% in an ophthalmic suspension. Prednisolone acetate is practically insoluble in water, so the product uses suspended drug particles rather than a true aqueous solution. The formulation must maintain uniform dosing after shaking and prevent excessive sedimentation or caking during storage. The FDA labeling identifies the product as an ophthalmic suspension and directs patients to shake it well before use.[1]

The labeled inactive ingredients include excipients associated with wetting, buffering, tonicity, viscosity, metal-ion control, preservation, and vehicle stability.

Formulation function	PRED MILD excipient or excipient class	Commercial purpose
Wetting and dispersion	Polysorbate 80	Helps wet hydrophobic prednisolone acetate particles
Viscosity and suspension control	Hypromellose	Slows sedimentation and supports dose uniformity
Buffering	Boric acid and sodium citrate	Controls pH and supports ocular tolerability
Tonicity adjustment	Sodium chloride	Helps approximate physiologic osmotic conditions
Chelation	Edetate disodium	Binds trace metals that can affect stability or preservation
Preservation	Benzalkonium chloride	Controls microbial growth in multidose packaging
Vehicle	Purified water	Provides the aqueous continuous phase

The exact commercial opportunity depends on matching the reference product’s critical quality attributes, not simply duplicating its ingredient list. FDA approval of an ophthalmic suspension requires control of particle-size distribution, assay, impurities, pH, osmolality, viscosity, sterility, preservative content, antimicrobial effectiveness, and container-closure integrity.[2]

What excipients are protected by the PRED MILD formulation?

The excipients themselves are generally not patent-protected as ingredients in PRED MILD. Boric acid, sodium citrate, sodium chloride, hypromellose, polysorbate 80, edetate disodium, and benzalkonium chloride are established pharmaceutical excipients with broad prior use.

The protectable value is more likely to reside in formulation relationships, such as:

• A defined prednisolone acetate particle-size distribution.
• A specific viscosity range that improves redispersibility.
• A pH and buffer system that balances suspension stability with ocular comfort.
• A preservative concentration compatible with multidose use.
• A manufacturing process that produces consistent particle morphology.
• A container and dispensing system that limits dose variability.
• A combination of excipients that limits caking, aggregation, or settling.

A generic manufacturer would normally seek an ANDA referencing the listed drug rather than attempting to secure broad composition-of-matter protection. Any new formulation patent would need to claim a measurable technical advantage, such as improved physical stability, reduced shaking requirements, lower preservative exposure, or better delivered-dose uniformity.

What is the FDA regulatory status of PRED MILD?

PRED MILD is an FDA-approved prescription ophthalmic corticosteroid product. The product is associated with prednisolone acetate ophthalmic suspension, 0.12%, and is identified in FDA drug databases as a sterile ophthalmic suspension.[1][3]

Regulatory item	PRED MILD position
Active ingredient	Prednisolone acetate
Strength	0.12% ophthalmic suspension
Dosage form	Ophthalmic suspension
FDA pathway for follow-on products	ANDA, subject to reference-product requirements
Biologic status	Not a biologic
Biosimilar pathway	Not applicable
Prescription status	Prescription ophthalmic drug
Primary regulatory challenge	Demonstrating pharmaceutical equivalence and product quality

The regulatory pathway is materially simpler than a biologic follow-on pathway because prednisolone acetate is a small-molecule drug. Biosimilar risk is therefore irrelevant. Competitive entry is more likely to come from ANDA applicants, branded reformulations, private-label ophthalmic products, and therapeutic substitutes.

What is the Orange Book status of PRED MILD?

Prednisolone acetate ophthalmic suspension is an old small-molecule product, and its original composition-of-matter and early product protections have expired. No meaningful period of new-drug exclusivity should be expected for the legacy product.

The commercial question is whether active patents are listed for the specific reference product and whether any remaining exclusivity blocks ANDA approval. FDA Orange Book records are the controlling source for listed patents, exclusivity, therapeutic equivalence codes, and reference-product status.[3]

A review of the public FDA framework indicates that PRED MILD does not present the type of active, high-value patent barrier associated with recently approved specialty drugs. The main entry risk is therefore technical and commercial rather than patent-based.

Exclusivity category	Expected PRED MILD position
New chemical entity exclusivity	Expired or not applicable
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current material barrier expected
Reference-product exclusivity	No current material barrier expected
Listed formulation patents	No material active barrier identified in the public FDA framework
ANDA entry risk	Primarily formulation, manufacturing, and market-access risk

Patent status can change through listing updates, litigation, or separate patents covering later formulations. A manufacturer should treat the FDA Orange Book record and current USPTO records as the operative sources for launch clearance.

When does PRED MILD lose exclusivity?

PRED MILD has already passed the exclusivity period associated with its original approval. Prednisolone acetate has been used in ophthalmic products for decades, and generic prednisolone acetate ophthalmic suspensions are commercially available in multiple strengths.

The relevant commercial timeline is therefore:

Milestone	Commercial implication
Original prednisolone acetate development	Historical composition and formulation rights have expired
PRED MILD approval	Established the 0.12% reference product
Generic prednisolone acetate development	Demonstrated feasibility of follow-on competition
Current market	Entry is constrained by ophthalmic manufacturing and physician substitution, not basic exclusivity
Future opportunity	Differentiated delivery, preservative reduction, and supply reliability

The absence of strong patent exclusivity does not guarantee rapid substitution. Ophthalmic suspensions require sterile manufacturing, validated filling, robust particulate control, and reliable bottle performance. These requirements limit the number of credible suppliers.

What formulation patents could be pursued for PRED MILD?

A new entrant could pursue patents around a modified formulation rather than the legacy PRED MILD composition.

Preservative-free suspension

A unit-dose or preservative-free multidose product could target patients with ocular-surface disease, chronic exposure to benzalkonium chloride, contact-lens-related sensitivity, or repeated postoperative treatment.

Potential claims could cover:

• A preservative-free prednisolone acetate suspension.
• A sterile unit-dose ampule or vial.
• A multidose system with a microbial barrier.
• A low-shear manufacturing process that preserves particle size.
• A formulation with equivalent stability without benzalkonium chloride.

The main technical barrier is microbial control after repeated opening. A preservative-free product needs an appropriate single-use format or validated dispensing technology.

Reduced-preservative formulation

A reduced-benzalkonium formulation could offer a lower-cost and lower-complexity alternative to a fully preservative-free product. The commercial benefit would be strongest if the formulation maintained microbial protection and chemical stability while reducing ocular-surface irritation.

Improved redispersibility

Suspensions can fail commercially when the drug cakes at the bottom of the bottle or requires prolonged shaking. A formulation patent could target:

• Narrower particle-size distribution.
• Controlled crystal morphology.
• Optimized hypromellose concentration.
• Alternative wetting agents.
• Reduced sedimentation volume.
• Faster redispersion after storage.

The performance claim should be supported by measurable shaking time, delivered-dose uniformity, sedimentation behavior, and accelerated-stability data.

Alternative rheology

Hypromellose increases viscosity and can improve suspension stability, but excessive viscosity may impair drop formation, blur vision, or create poor patient acceptance. A modified rheology system could target a narrower balance between physical stability and dispensing performance.

Device and container patents

Commercial differentiation can arise from the delivery system rather than the liquid composition:

• Metered-dose ophthalmic dispensers.
• Low-residual-volume bottles.
• One-handed dispensing systems.
• Orientation-independent delivery.
• Tamper-evident multidose systems.
• Packaging that improves suspension redispersion.

Device claims can create a secondary barrier even when the active ingredient and core excipients are generic.

How strong is the PRED MILD patent estate?

The legacy PRED MILD patent estate appears weak relative to newer ophthalmic products protected by active formulation, device, or method-of-use patents. Prednisolone acetate is an established corticosteroid, and its primary chemical protection has expired.

Patent dimension	Assessment
Active-ingredient protection	Expired
Core 0.12% formulation protection	Likely limited
Excipient protection	Weak because the excipients are well established
Device opportunity	Moderate if the delivery system improves performance
Process opportunity	Moderate if the process produces non-obvious quality benefits
Method-of-use opportunity	Limited for legacy indications; stronger only for new, specific uses
Freedom-to-operate risk	More relevant to formulation and device patents than to prednisolone acetate itself

A new patent estate would need claims that survive obviousness challenges. Simply replacing one conventional excipient with another would generally provide limited defensibility unless the change produces an unexpected and documented result.

What generic entry risks exist for PRED MILD?

Generic entry risk is high from a legal-exclusivity perspective and moderate from an execution perspective.

Legal and regulatory entry risk

An ANDA applicant could challenge any listed patent through a Paragraph IV certification. If no unexpired listed patent blocks approval, the applicant could file with a Paragraph III certification or a certification that no relevant patent is listed, depending on the applicable Orange Book record.[4]

Potential Paragraph IV issues would involve:

• Active listed patents for the reference product.
• Patents covering a specific suspension formulation.
• Device patents associated with the dispensing bottle.
• Method-of-use patents with relevant labeling.
• Patent-term extensions or pediatric extensions.

No major Paragraph IV dispute associated specifically with PRED MILD is established in the core public regulatory record. Product-specific litigation should be checked against FDA records, PACER, and relevant district-court dockets before a launch decision.

Technical entry risk

The principal technical risks are:

1. Failure to match suspension particle-size distribution.
2. Inadequate redispersibility.
3. Poor delivered-dose uniformity.
4. Preservative content outside specification.
5. Instability in the proposed bottle.
6. Sterility or container-closure failures.
7. Excessive viscosity or unacceptable drop size.
8. Bioequivalence difficulties for an ophthalmic suspension.

For ophthalmic suspensions, pharmaceutical equivalence is not limited to active-ingredient assay. The applicant must control formulation and performance attributes that affect dose delivery and local exposure.

Which companies challenge or compete with PRED MILD?

Competition comes from several groups rather than from one direct challenger.

Competitor group	Examples	Competitive basis
Generic prednisolone acetate	Generic 0.12% and 1% suspensions	Price and formulary substitution
Branded prednisolone products	PRED FORTE and other prednisolone acetate products	Physician familiarity and strength differentiation
Other topical steroids	Loteprednol, fluorometholone, dexamethasone	Tolerability, potency, indication, and branding
Combination products	Steroid-antibiotic ophthalmic products	Convenience and postoperative use
Specialty delivery products	Preservative-free or advanced dispensing formats	Ocular-surface tolerability and adherence

PRED MILD occupies a lower-strength niche than prednisolone acetate 1%. Its commercial positioning may appeal where clinicians want corticosteroid therapy but prefer a lower concentration or a particular established product profile.

How does PRED MILD compare with competing ophthalmic steroids?

Product category	Typical commercial advantage	Main limitation
PRED MILD, prednisolone acetate 0.12%	Established corticosteroid suspension and lower strength	Requires shaking; preservative exposure may limit chronic use
Prednisolone acetate 1%	Higher anti-inflammatory potency and broad physician familiarity	Greater steroid exposure and similar suspension burden
Loteprednol etabonate	Often positioned around improved steroid-safety profile	Higher cost and separate patent or brand considerations
Fluorometholone	Lower-potency steroid option	May be less effective for some inflammatory conditions
Dexamethasone solutions or suspensions	Established potency and multiple dosage forms	Safety and formulation characteristics differ
Prednisolone sodium phosphate solution	Clear solution and no suspended particles	Different active ingredient and clinical profile

The strongest commercial substitute depends on diagnosis, postoperative protocol, payer policy, physician preference, and the patient’s ocular-surface tolerance.

What licensing deals and partnership opportunities exist?

The most plausible licensing opportunities do not involve the expired prednisolone acetate molecule. They involve enabling technologies.

Potential deal structures include:

• Licensing a preservative-free ophthalmic suspension platform.
• Co-developing a metered multidose delivery system.
• Acquiring a regional ANDA or approved product.
• Licensing sterile fill-finish capacity.
• Partnering with an ophthalmic contract manufacturer.
• Developing a private-label product for pharmacy or managed-care channels.
• Combining prednisolone acetate with a proprietary bottle or closure system.

A formulation owner could license the technology to a generic manufacturer with ANDA experience. A manufacturer with sterile ophthalmic capacity could instead pursue an internal product and reserve licensing for regional commercialization.

What revenue exposure and commercial upside does PRED MILD offer?

PRED MILD should be treated as a niche ophthalmic product rather than a blockbuster opportunity. Its revenue potential depends on:

• The size of the 0.12% prednisolone acetate segment.
• Generic price erosion.
• Product availability and backorder performance.
• Payer substitution.
• Brand loyalty among ophthalmologists.
• Differentiation through preservative-free delivery.
• Access to ophthalmology-focused sales channels.

The larger revenue opportunity may come from a platform strategy covering several ophthalmic corticosteroid products. A company could use the same sterile suspension, bottle, and preservative-reduction technology across prednisolone acetate, fluorometholone, or other poorly water-soluble ophthalmic drugs.

Commercial scenarios include:

Scenario	Product strategy	Expected economics
Low-cost generic	Conventional multidose suspension	High volume potential, low margin
Authorized or branded generic	Reliable supply and physician continuity	Moderate margin, limited differentiation
Preservative-reduced product	Improved tolerability positioning	Higher price potential
Preservative-free unit dose	Ocular-surface and postoperative niche	Higher manufacturing and packaging cost
Device-led product	Improved dosing and adherence	Patentable differentiation and premium pricing
Platform portfolio	Multiple ophthalmic suspensions	Better manufacturing utilization and channel leverage

Public sources do not establish a reliable standalone revenue figure for PRED MILD. Product-level revenue may be private, aggregated with broader ophthalmology sales, or unavailable.

What manufacturing and intellectual-property barriers matter most?

The key barrier is sterile ophthalmic manufacturing. A credible commercial entrant needs:

• Validated aseptic processing or terminal-sterilization compatibility.
• Controlled micronization or particle-size reduction.
• Homogeneous suspension processing.
• Low-bioburden excipient handling.
• Sterile filling and capping.
• Container-closure integrity testing.
• Extractables and leachables assessment.
• Stability data in the proposed package.
• Robust in-process mixing before filling.
• Controls that prevent concentration gradients between filled units.

The process must also maintain uniformity through shipping and storage. Sedimentation, caking, aggregation, and nozzle clogging can create regulatory and product-liability exposure even when the assay is acceptable.

Geographically, the strongest commercial opportunity is in the United States because FDA-approved generic ophthalmic products can access a large prescription market. Europe, Canada, Japan, and emerging markets require separate regulatory submissions and may apply different rules to substitution, preservative content, device qualification, and ophthalmic bioequivalence.

What is the commercial launch strategy for a PRED MILD generic?

A practical launch strategy has four phases:

1. Reference characterization. Measure particle size, morphology, viscosity, pH, osmolality, sedimentation, redispersibility, preservative content, and delivered-dose uniformity.
2. ANDA formulation development. Match critical quality attributes while controlling manufacturing variability and container performance.
3. Differentiated line extension. Develop a preservative-reduced, preservative-free, or device-enhanced version with separate intellectual-property protection.
4. Channel commercialization. Target ophthalmology wholesalers, group purchasing organizations, managed-care formularies, hospitals, ambulatory surgery centers, and private-label partners.

The conventional generic has the fastest route to market but faces price competition. The differentiated version has stronger margin potential but requires more clinical, regulatory, manufacturing, and market-access work.

Key Takeaways

• PRED MILD is prednisolone acetate ophthalmic suspension, 0.12%.
• Its commercial value depends on suspension performance, sterile manufacturing, packaging, and patient tolerability.
• The listed excipients support wetting, viscosity, buffering, tonicity, chelation, preservation, and vehicle stability.
• The legacy active ingredient and core product rights do not create a strong current exclusivity barrier.
• Biosimilar risk is not relevant because prednisolone acetate is a small molecule.
• Generic entry risk is high legally but constrained by ophthalmic suspension manufacturing and quality requirements.
• The strongest new intellectual-property opportunities involve preservative-free delivery, improved redispersibility, particle engineering, and dispensing devices.
• A conventional generic is likely to face price erosion; a platform or differentiated product can support better margins.
• PRED MILD is most attractive as part of a broader ophthalmic suspension portfolio rather than as a standalone blockbuster product.

FAQs

Is PRED MILD a solution or a suspension?

PRED MILD is a suspension. Prednisolone acetate is dispersed as solid particles in an aqueous vehicle, which is why the product must be shaken before use.

Why does PRED MILD contain hypromellose?

Hypromellose increases viscosity and helps maintain a more uniform suspension. Its concentration must be controlled because excessive viscosity can impair drop formation and patient acceptability.

Can PRED MILD be reformulated without benzalkonium chloride?

Yes, a preservative-free version could be developed, but it would require suitable single-dose packaging or validated multidose microbial-barrier technology and a complete stability and sterility strategy.

Is prednisolone acetate ophthalmic suspension difficult to make?

It is more technically demanding than a simple ophthalmic solution because particle size, sedimentation, redispersibility, dose uniformity, sterility, and bottle performance must be controlled together.

What is the most defensible patent strategy for a new PRED MILD competitor?

The strongest strategy would generally focus on a measurable formulation or device advantage, such as preservative-free multidose delivery, improved redispersibility, controlled particle morphology, lower delivered-dose variability, or a proprietary dispensing system.

References

1. U.S. Food and Drug Administration. (n.d.). PRED MILD- prednisolone acetate suspension prescribing information. DailyMed/FDA labeling database.

2. U.S. Food and Drug Administration. (2008). Guidance for industry: Ophthalmic drug products produced and packaged with a microbiologically controlled manufacturing process. FDA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format guidance for industry. FDA.